Fulgent Genetics, Inc. 8-K

What Happened

• Fulgent Genetics’ wholly owned subsidiary Inform Diagnostics closed two transactions on March 17, 2026: the purchase of all equity of Dermatopathology Experts, LLC (StrataDx) and the acquisition of substantially all assets related to Bako Pathology’s dermatopathology, podiatric pathology, molecular diagnostics and therapeutic products.
• The equity purchase (PSA) had a base price of $12.5 million; buyer-paid cash at closing was approximately $13.5 million (subject to post-closing adjustments). The asset purchase (APA) had a base price of $43.0 million; buyer-paid cash at closing was approximately $43.4 million (subject to post-closing adjustments). Inform Diagnostics also paid certain seller indebtedness and transaction expenses and funded escrows to secure adjustments.
• Fulgent and Consonance Capital Partners issued a joint press release announcing the closings (attached as Exhibit 99.1 to the 8-K).

Key Details

• Closing date: March 17, 2026.
• PSA purchase: StrataDx — base price $12.5M; approximately $13.5M paid at closing (cash).
• APA purchase: Bako-related assets — base price $43.0M; approximately $43.4M paid at closing (cash).
• Lease assignment: Inform assumed a 29,099 sq ft commercial lease at 6240 Shiloh Road, Alpharetta, GA (term through July 31, 2032); base rent $15.54/sq ft starting Aug 1, 2025, with 2% annual increases; tenant pays operating expenses.

Why It Matters

• These acquisitions expand Fulgent’s diagnostics and pathology footprint by adding StrataDx and Bako’s dermatopathology, podiatry pathology and related molecular services, potentially increasing test volume, capabilities and revenue opportunities for Inform Diagnostics and Fulgent.
• The company used cash at closing, assumed lease obligations and established escrows for purchase‑price adjustments — facts investors should watch when assessing near‑term cash flow, balance sheet impact and integration costs.
• Investors should monitor future disclosures for post-closing adjustments, any required financial statements of the acquired businesses, and guidance on how these assets will be integrated into Fulgent’s operations.